Suspension of Medical Research at West Los Angeles and Sepulveda VA Medical Facilities and Informed Consent and Patient Safety in VA Medical Research: Joint Hearing Before the Subcommittee on Oversight and Investigations and Subcommittee on Health of the Committee on Veterans' Affairs, House of Representatives, One Hundred Sixth Congress, First Session, April 21, 1999 |
From inside the book
Results 1-5 of 27
Page 20
... performance site is across the street at the VA Medical Center . We would have an expectation of review by IRBS at both places . What we find today is that , apparently , some num- ber of HHS awards to UCLA where the performance site ...
... performance site is across the street at the VA Medical Center . We would have an expectation of review by IRBS at both places . What we find today is that , apparently , some num- ber of HHS awards to UCLA where the performance site ...
Page 24
... performance and safety of our human research in the Department of Veterans Affairs . The concern that the members of your subcommittee have ex- pressed about the issue of safety and human research at our facil- ity is exactly the ...
... performance and safety of our human research in the Department of Veterans Affairs . The concern that the members of your subcommittee have ex- pressed about the issue of safety and human research at our facil- ity is exactly the ...
Page 26
... performance issues . Be assured we do care deeply about veterans and public health , and we hope it becomes apparent that we did markedly improve human research safety at West LA . Furthermore , as several of you have indicated , the ...
... performance issues . Be assured we do care deeply about veterans and public health , and we hope it becomes apparent that we did markedly improve human research safety at West LA . Furthermore , as several of you have indicated , the ...
Page 105
... performance and safety of biomedical research for the Department of Veterans Affairs . The information I will present is from our own experience at the West Los Angeles VA Medical Center but it will have implications for the system at ...
... performance and safety of biomedical research for the Department of Veterans Affairs . The information I will present is from our own experience at the West Los Angeles VA Medical Center but it will have implications for the system at ...
Page 106
... Performance Improvement in 1997 ; and receive Accreditation with Commendation from the Joint Commission of Accreditation of Hospitals in 1998 . The measures described above have had a significant impact on improving the safety and ...
... Performance Improvement in 1997 ; and receive Accreditation with Commendation from the Joint Commission of Accreditation of Hospitals in 1998 . The measures described above have had a significant impact on improving the safety and ...
Other editions - View all
Common terms and phrases
action appropriate approved BUYER cardiology Chairman Chief of Staff Common Rule compliance conducted Cooperative Studies Program costs CRDO CSEC CSP study CSP/VA Headquarters CSPCC CSPCRPCC Data Monitoring Board Department of Veterans doctor drug ERIN MORIARTY ethical EVERETT facility Federal FEUSSNER Footage funding GLAHS Health hospital human research Human Rights Committee Human Studies informed consent Institutional Review Board issues KIZER March 22 medical research meeting MORIARTY NBAC NORMAN October 30 Office OPRR oversight PANDOL participating medical centers patients planning Principal Proponent problems procedures proposed Protection of Human protocol psychiatric PUGLISI R&D Committee recommendations regulations Research and Development research involving research program research project research subjects responsible risk Sager SANTANA schizophrenia Shalmah Shamoo SNYDER specific SPENCER Study Biostatistician Study Chairperson Study CRP Subcommittee Thank treatment UCLA VA Medical Center VAMC Veterans Affairs Voiceover West Los Angeles
Popular passages
Page 98 - A statement that the study Involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental...
Page 99 - A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained; (6) For research involving more than minimal risk, an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained; (7) An explanation of whom to contact for answers to pertinent questions about the research and research subjects'...
Page 205 - ... responses outside the research could reasonably place the subjects at risk of criminal or civil liability or be damaging to the subjects' financial standing, employability, or reputation.
Page 197 - ... short form. (c) An IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either: (1) That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality.
Page 205 - ... these sources are publicly available or if the information is recorded by the investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects.
Page 210 - The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject...
Page 96 - Department of Agriculture Department of Commerce Department of Defense Department of Education Department of Energy Department of Health and Human Services...
Page 193 - The IRB should not consider possible longrange effects of applying knowledge gained in the research (for example, the possible effects of the research on public policy) as among those research risks that fall within the purview of its responsibility.
Page 210 - A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable.
Page 98 - An IRB shall conduct continuing review of research covered by this policy at intervals appropriate to the degree of risk, but not less than once per year, and shall have authority to observe or have a third party observe the consent process and the research.